TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01845077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2x500 mg Metformin (Glumetza)
Description: 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Linagliptin/1000 mg Metformin FDC
Description: FDC tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Linagliptin (Tradjenta)
Description: 1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Linagliptin (Tradjenta)
Description: 1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3x500 mg Metformin (Glumetza)
Description: 3 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Linagliptin (Tradjenta)
Description: 1 tablet
Study: NCT01113476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
Study: NCT05851001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation exercise
Description: This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Muscle relaxation exercise
Description: The participant was asked to listen to relaxation music for 30 minutes in a private room.
Study: NCT02618395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 - Hydrocodone
Description: Hydrocodone-acetaminophen
Study: NCT00180700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Study: NCT03574779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
Study: NCT00746447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine granules
Description: 3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine granules
Description: 1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine granules
Description: 0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
Study: NCT03973801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
Study: NCT01845077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 x 500 mg Metformin (Glumetza)
Description: 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Linagliptin/1000mg Metformin FDC
Description: FDC Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Description: 2 FDC tablets
Study: NCT03574779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m\^2) on Day 1 of every 21-day cycle
Study: NCT01578746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral approach in total hip arthroplasty
Description: The use of direct lateral approach in total hip arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior approach
Description: The use of anterior approach in total hip arthroplasty
Study: NCT01018056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
Study: NCT01865071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop ileostomi
Study: NCT03924271

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron deficiency testing
Description: Blood sample for complete iron status
Study: NCT03828292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered as an intravenous infusion.
Study: NCT03725059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (K)
Description: IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (P)
Description: Normal saline or dextrose IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (X)
Description: IV infusion QW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel (X)
Description: IV infusion QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A)
Description: IV infusion either in Q2W or Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin (A)
Description: IV infusion either in Q2W or Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin (E)
Description: IV infusion either in Q2W or Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin (E)
Description: IV infusion either in Q2W or Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C)
Description: IV infusion either in Q2W or Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide (C)
Description: IV infusion either in Q2W or Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Variable endocrine therapy for up 10 years

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Variable radiation therapy per local standard of care

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation therapy
Description: Variable radiation therapy per local standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for breast cancer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Surgery for breast cancer
Study: NCT04218682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shadow's Edge Mobile Application Gameplay
Description: 6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
Study: NCT01009242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: Single dose:~1 mg/kg CDP6038 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: Single dose:~0.1mg/kg CDP6038 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: Single dose:~1.0mg/kg CDP6038 SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Single dose:~Placebo IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Single dose:~Placebo SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP 6038 SC
Description: Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Individual stable doses of methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Individual stable doses of methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Individual stable doses of methotrexate.
Study: NCT05098236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the Blind Field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training in the Sighted Field
Description: This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
Study: NCT04882215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT combined with WMU Training
Description: GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GMT combined with WMU Training
Description: GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial.
Study: NCT03815019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iKanEat Behavioral Intervention
Description: The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: iKanEat Behavioral Intervention
Description: The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding.
Study: NCT03225989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOAd703
Description: Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
Study: NCT02822755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program and Adherence Logs
Description: Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program and Adherence Logs
Description: Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
Study: NCT03075631

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires
Study: NCT04026282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GnRH-ant protocol
Description: Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GnRH-a long protocol
Description: The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
Study: NCT03828292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib solution for injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules will be administered orally.
Study: NCT04735900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid biopsy sampling
Description: Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
Study: NCT01690832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard saline infusion
Description: i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard saline infusion
Description: i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenoldopam infusion
Description: combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
Study: NCT03373812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blepharoptosis repair
Description: levator advancement or mullerectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blepharoptosis repair
Description: levator advancement or mullerectomy
Study: NCT00148590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
Study: NCT02633111

Intervention type: OTHER
Intervention: collected at pre-treatment tumor biopsy
Description: to identify the tumor-specific clonotype

Intervention type: OTHER
Intervention: Peripheral blood tests
Description: for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
Study: NCT00854854

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TKCell
Description: TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8
Study: NCT01400633

Intervention type: DRUG
Intervention: decitabine injection
Description: decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks